Weve all heard that stopping taking a GLP-1 medication for weight losssuch as semaglutide (marketed as Wegovy) and tirzepatide (sold as Zepbound)often leads to rapid weight gain, with people returning to baseline in as little as 18 months
Journal of Clinical and Translational Hepatology
Since GLP-1 RAs are often prescribed to patients with obesity, this single unmeasured factor could be the true driver of the observed risk. Demetrios Vavvas, MD, PhD Second, the results may be influenced by surveillance bias, Vavvas continued
People with obesity or diabetes can have low vitamin B12 (especially if they take metformin, a common diabetes drug)
The risk of AD significantly increases with age, particularly after 65 years old [5]
doi: 10.1111/dom.15058 85 GersteinHCSattarNRosenstockJRamasundarahettigeCPratleyRLopesRDet al